In a paradox obesity is a net positive for cuttingedge anticancer drugs

first_img In a paradox, obesity is a ‘net positive’ for cutting-edge anticancer drugs Email Sign up for our daily newsletter Get more great content like this delivered right to you! Country Dennis Kunkel Microscopy/Science Source Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Click to view the privacy policy. Required fields are indicated by an asterisk (*)center_img Obesity can have surprising effects on T cells, such as this one on lung cancer cells. Second only to smoking, obesity is a top risk factor for cancer. But cancer doctors have noticed something surprising: Overweight patients sometimes respond better than other patients to powerful drugs that harness the immune system to fight tumors. Now, researchers tracing the complex effects of obesity on cancer are glimpsing a possible explanation: Obesity weakens the immune system and favors tumor growth by boosting the very same molecules those drugs target.“For the most part, everybody assumes obesity is always bad. But [with these drugs], there was a net positive,” says cancer immunologist William Murphy of the University of California (UC), Davis, who, with UC Davis oncologist Arta Monjazeb, led the work reported today in Nature Medicine. Murphy thinks the finding could point to ways to make the drugs more effective in all cancer patients.Called checkpoint inhibitors, the drugs work by blocking the activation of PD-1, a protein on the surface of immune sentinels called T cells. The body naturally triggers PD-1 to dampen immune responses, but tumors can also stimulate PD-1 to protect themselves. Lifting this molecular “brake” allows the T cells to attack the cancer cells. PD-1 inhibitors have caused untreatable tumors to vanish for years in people with melanoma, lung cancer, and some other cancer types. By Jocelyn KaiserNov. 12, 2018 , 11:00 AM But only a minority of patients respond to the drugs, and a study early this year in The Lancet Oncology showed that the responders disproportionately include people who are overweight. In 330 advanced melanoma patients given a PD-1 inhibitor, researchers at MD Anderson Cancer Center in Houston, Texas, found that those who were male and overweight lived much longer on average: nearly 27 months compared with 14 months for patients with a normal body mass index (BMI).Now, Murphy’s team has firmed up this clinical observation in the lab and identified a possible basis. After confirming that tumors grow faster in obese mice, his team studied the T cells of obese mice, monkeys, and people. They found that the cells were what immunologists call “exhausted.” They were slow to proliferate and had stopped making secreted proteins that stimulate other immune system helpers. They also displayed more PD-1 than average, meaning cancer cells could more easily suppress them and grow unhindered.Leptin, a hormone made by fat cells, is one factor in the PD-1 excess, Murphy’s group found. Overweight animals and people produce high levels of the hormone, which normally signals the brain that the animal has had enough to eat. But leptin also affects the immune system, and the UC Davis team suspects it triggers a signaling pathway that increases PD-1 on T cells.The PD-1 excess also has a paradoxical benefit: In obese mice, it makes T cells unusually responsive to PD-1 inhibitors, Murphy’s team reports today in Nature Medicine. Once the drugs released this brake, the T cells sprang back into action. Nourished by glucose and other nutrients abundant in an overweight animal’s tissues, they worked better at curbing tumors than in normal weight animals.The finding suggests an “unexpected” benefit of obesity for cancer patients, says Harvard University immunologist Lydia Lynch. Her group reports in Nature Immunology today on a different way obesity impairs the immune system’s ability to attack tumors: by hampering a type of immune cell called natural killer cells that seek out and destroy abnormal cells.Murphy plans to explore whether briefly giving normal weight mice with cancer a high-fat diet in order to mimic some effects of obesity could boost their response to PD-1 inhibitors. But such treatments for cancer patients could also have harmful effects, cautions tumor immunologist Suzanne Ostrand-Rosenberg of The University of Utah in Salt Lake City, who also studies how obesity spurs tumor growth. “It’s a balance here, a very careful balance,” Ostrand-Rosenberg says.Whereas the UC Davis team’s findings suggest obese patients may respond better to PD-1 drugs, normal weight patients can also benefit and it’s too early to make treatment decisions based on BMI, says MD Anderson melanoma researcher Jennifer McQuade, lead author on The Lancet Oncology study. “Ultimately, we need an integrative analysis to understand the contributions of BMI, sex, age, and how these interact with each other,” McQuade says.*Correction, 13 November, 11:50 a.m.: An earlier version of this article incorrectly stated that Murphy planned to give normal weight mice leptin to boost their response to PD-1 inhibitors.last_img read more